Estimating the causal effects of modifiable, non-genetic factors on Huntington disease progression using propensity score weighting.


Journal

Parkinsonism & related disorders
ISSN: 1873-5126
Titre abrégé: Parkinsonism Relat Disord
Pays: England
ID NLM: 9513583

Informations de publication

Date de publication:
02 2021
Historique:
received: 16 07 2020
revised: 07 01 2021
accepted: 10 01 2021
pubmed: 22 1 2021
medline: 28 12 2021
entrez: 21 1 2021
Statut: ppublish

Résumé

Despite being genetically inherited, it is unclear how non-genetic factors (e.g., substance use, employment) might contribute to the progression and severity of Huntington's disease (HD). We used propensity score (PS) weighting in a large (n = 2914) longitudinal dataset (Enroll-HD) to examine the impact of education, employment status, and use of tobacco, alcohol, and recreational and therapeutic drugs on HD progression. Each factor was investigated in isolation while controlling for 19 other factors to ensure that groups were balanced at baseline on potential confounders using PS weights. Outcomes were compared several years later using doubly robust models. Our results highlighted cases where modifiable (non-genetic) factors - namely light and moderate alcohol use and employment - would have been associated with HD progression in models that did not use PS weights to control for baseline imbalances. These associations did not hold once we applied PS weights to balance baseline groups. We also found potential evidence of a protective effect of substance use (primarily marijuana use), and that those who needed antidepressant treatment were likely to progress faster than non-users. Our study is the first to examine the effect of non-genetic factors on HD using a novel application of PS weighting. We show that previously-reported associated factors - including light and moderate alcohol use - are reduced and no longer significantly linked to HD progression after PS weighting. This indicates the potential value of PS weighting in examining non-genetic factors contributing to HD as well as in addressing the known biases that occur with observational data.

Identifiants

pubmed: 33476879
pii: S1353-8020(21)00026-2
doi: 10.1016/j.parkreldis.2021.01.010
pmc: PMC7949328
mid: NIHMS1665384
pii:
doi:

Substances chimiques

Antidepressive Agents 0

Types de publication

Journal Article Observational Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

56-62

Subventions

Organisme : Medical Research Council
ID : MR/M008592/1
Pays : United Kingdom
Organisme : NIDA NIH HHS
ID : R01 DA045049
Pays : United States

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Références

Neurobiol Dis. 2013 Oct;58:179-82
pubmed: 23732677
Mov Disord. 2010 Nov 15;25(15):2595-603
pubmed: 20623772
Mov Disord. 2010 Jul 30;25(10):1444-50
pubmed: 20629137
Mov Disord. 2011 Jul;26(8):1489-95
pubmed: 21432905
J Neurol. 2012 Sep;259(9):1824-31
pubmed: 22274789
Eur J Neurosci. 2005 Oct;22(8):2081-8
pubmed: 16262645
Psychiatry Res. 2010 Jul 30;178(2):414-8
pubmed: 20471695
Neurobiol Dis. 2008 Jun;30(3):312-322
pubmed: 18403212
PLoS One. 2011;6(7):e22133
pubmed: 21760962
Neurology. 2017 Dec 12;89(24):2495-2502
pubmed: 29142089
Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3498-503
pubmed: 14993615
Res Commun Chem Pathol Pharmacol. 1991 Nov;74(2):167-84
pubmed: 1839809
Lancet Neurol. 2017 Sep;16(9):701-711
pubmed: 28642124
Stat Sci. 2007;22(4):569-573
pubmed: 18516239
Nat Genet. 1993 Aug;4(4):398-403
pubmed: 8401589
Arch Med Res. 2008 Apr;39(3):265-76
pubmed: 18279698
Nat Genet. 1993 Aug;4(4):393-7
pubmed: 8401588
Mov Disord. 1996 Mar;11(2):136-42
pubmed: 8684382
Neurology. 2017 Feb 28;88(9):909-915
pubmed: 28148631
Eur J Pharmacol. 2015 Dec 15;769:33-42
pubmed: 26511378
Am J Hum Genet. 1997 May;60(5):1202-10
pubmed: 9150168
JAMA Neurol. 2013 Nov;70(11):1382-8
pubmed: 24000094
J Neurol Sci. 1987 Sep;80(2-3):299-306
pubmed: 2960786
Nat Genet. 1993 Aug;4(4):387-92
pubmed: 8401587
Arch Neurol. 1991 Aug;48(8):800-4
pubmed: 1832854
Neurology. 1979 Jan;29(1):1-3
pubmed: 154626
Mov Disord. 2018 Mar;33(3):472-478
pubmed: 29297592
Am J Med Genet B Neuropsychiatr Genet. 2010 Mar 5;153B(2):397-408
pubmed: 19548255

Auteurs

Beth Ann Griffin (BA)

RAND Center for Causal Inference, RAND Corporation, 1200, South Hayes Street, Arlington, VA, USA. Electronic address: bethg@rand.org.

Marika Suttorp Booth (MS)

RAND Corporation, 1776, Main Street, Santa Monica, CA, USA.

Monica Busse (M)

Centre for Trials Research, Cardiff University, Neuadd Merionydd, Heath Park, CF14 4XN, Cardiff, UK.

Edward J Wild (EJ)

Huntington's Disease Centre, UCL Institute of Neurology, London, WC1N 3BG, UK.

Claude Setodji (C)

RAND Center for Causal Inference, RAND Corporation, 4570, Fifth Ave #600, Pittsburgh, PA, USA.

John H Warner (JH)

CHDI Management/CHDI Foundation, 155 Village Boulevard, Suite 200, Princeton, NJ, USA.

Cristina Sampaio (C)

CHDI Management/CHDI Foundation, 155 Village Boulevard, Suite 200, Princeton, NJ, USA.

Amrita Mohan (A)

CHDI Management/CHDI Foundation, 155 Village Boulevard, Suite 200, Princeton, NJ, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH